Diclomex

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Diclomex

Quick Facts

Property Description
Active Ingredient Diclofenac (typically as Sodium or Potassium salt)
General Forms Tablets, Capsules, Gels, Injectable Solution
Pharmacological Class Nonsteroidal Anti-Inflammatory Drug (NSAID)
General Purpose Relief from pain and inflammation symptoms
Origin Synthetic Compound (Phenylacetic acid derivative)

What is Diclomex and its Pharmacological Class?

Diclomex is the trade designation for a medicine whose active substance is Diclofenac, which is formally classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). This places it in the major therapeutic class of synthetic compounds used to manage symptoms related to pain and inflammation. Diclofenac is a specific type of NSAID known chemically as a phenylacetic acid derivative, distinguishing it from other common pain relievers. The active component is typically prepared as a salt, such as Diclofenac Sodium or Diclofenac Potassium, which is utilized to optimize its dissolution and absorption within its single-ingredient formulation. Diclofenac is used as an NSAID to decrease inflammation and pain in the body, easing discomfort by reducing swelling and redness.


Diclofenac's Origin, Forms, and General Purpose

The active ingredient, Diclofenac, is a synthetic compound that addresses discomfort by interfering with the body's natural chemical signals that cause pain and swelling. Diclomex is generally intended to provide broad symptomatic relief by utilizing its anti-inflammatory properties to temper the underlying processes of inflammation and the sensation of pain. The drug's mechanism involves the inhibition of cyclooxygenase enzymes, an action characteristic of the NSAID class. The drug works primarily by blocking the chemical production that drives discomfort. This medicine is available in multiple forms suitable for either systemic absorption or topical action, including standard oral tablets or capsules, specialized topical gels or creams, and sometimes an injectable solution, allowing the medication to be delivered appropriately depending on the required site of action. The variety of presentations is a key differentiating factor, making Diclofenac a versatile treatment option.

Regulatory References

  1. Diclofenac - StatPearls - NCBI Bookshelf

What side effects are possible with Diclomex?

Possible Side Effects and Safety Information

The safety profile of Diclomex, whose active ingredient is Diclofenac (an NSAID), is formally documented by regulatory authorities, with adverse reactions classified by frequency and affected body system.

Officially Documented Adverse Reactions

Common adverse reactions (occurring in 1% to 10% of individuals) primarily involve the Gastrointestinal System, and may include symptoms such as nausea, abdominal pain, diarrhea, indigestion (dyspepsia), and flatulence. Other common effects include headache and dizziness, along with transient increases in liver enzymes.

Serious Systemic Risks and Safety Patterns

Official labeling emphasizes a risk of serious adverse reactions associated with the NSAID class, which may occur without warning symptoms:

  • Gastrointestinal Risk: There is a documented risk of serious GI events, including bleeding, ulceration, and perforation of the stomach or intestines, which can be potentially fatal. This risk may increase with the duration of use.
  • Cardiovascular Thrombotic Risk: The medicine is associated with an increased risk of serious cardiovascular thrombotic events, such as Myocardial Infarction and Stroke. This risk may occur early in treatment and may be greater with higher doses and longer exposure.

Safety Constraints and Special Populations

Specific limitations on use are defined in regulatory documents. Diclofenac is contraindicated for patients with established congestive heart failure (NYHA Class II-IV), severe renal or hepatic failure, and is contraindicated for treating pain following Coronary Artery Bypass Graft (CABG) surgery. It is also contraindicated in individuals with a history of allergic-type reactions (e.g., asthma, urticaria) to aspirin or other NSAIDs. Use must be avoided during the third trimester of pregnancy (starting at 30 weeks gestation).

This framework of frequency-based effects and formal safety constraints structures the official understanding of the medicine's risk profile.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of diclofenac, the active substance in Diclomex, is formally documented in regulatory labeling to present with specific clinical manifestations that require immediate medical attention.

Documented Manifestations and Severe Outcomes

Acute overdose primarily affects the gastrointestinal (GI) and central nervous systems (CNS). Documented GI signs include nausea, vomiting, and epigastric pain, alongside CNS effects such as drowsiness, tinnitus, and confusion.

Severe overdose carries the risk of life-threatening systemic outcomes, including acute renal failure (kidney damage) and hepatic damage (liver injury). Profound CNS depression may escalate to seizures or coma. The regulatory labeling notes that patients with pre-existing renal or hepatic impairment may face an increased risk of severe organ damage following an overdose.

Required Emergency Actions

Official guidance mandates that immediate medical attention must be sought if an overdose is suspected. Urgent hospitalization is required for life-threatening presentations, such as respiratory depression. Management is limited to symptomatic and supportive treatment because regulatory documents explicitly state that no specific antidote is known. Procedures like gastric lavage or administration of activated charcoal may be considered as part of the supportive care if ingestion was recent.

Therapeutic Uses of Diclomex

What Diclomex Treats: Main Uses and Benefits

Diclomex is commonly used to address symptoms related to physical discomfort and inflammatory or irritative states. It may be part of symptomatic management for conditions like osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, which are conditions characterized by periods of heightened symptoms.

It helps ease pain and swelling, which assists with maintaining functional stability during symptomatic periods. The medication is applied in addressing symptom clusters that may become intense or disruptive, such as the pain associated with soft tissue injuries like sprains or strains, acute flare-ups like gout, and the severe, episodic manifestations of migraine attacks and primary dysmenorrhea (menstrual cramps).

In these contexts, Diclomex offers symptomatic relief that helps patients cope more steadily with symptom fluctuations when supportive symptom management is appropriate.


Quick Fact: Relief for Inflammatory Symptoms
Primary Focus Managing symptoms related to inflammatory or irritative states.
Benefit Aim Contributes to improved comfort and assists with maintaining functional stability.
Scenarios Relevant in acute or recurrent episodic manifestations.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Diclomex — Official Regulatory Information

The eligibility for Diclomex (Diclofenac) is strictly defined by regulatory authorities, outlining populations that are permitted, restricted, or absolutely forbidden to use the medicine.

Contraindicated Populations

Use is strictly forbidden in patients with known hypersensitivity to Diclofenac or any other NSAID, particularly if they have a history of asthma, urticaria, or angioedema precipitated by aspirin. It is contraindicated in the last trimester of pregnancy (from 30 weeks gestation) and in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Condition-Specific Non-Eligibility

Absolute non-eligibility is defined by severe pre-existing conditions, including active gastric or intestinal ulcer, bleeding, or perforation, severe heart failure (NYHA Class II–IV), and established ischemic heart disease. It is also contraindicated in cases of Hepatic failure and severe Renal failure (GFR <15 mL/min/1.73m^2).

Age and Conditional Use Rules

Adults are the standard eligible population. However, safety and efficacy have not been established for the general pediatric population (typically under 12 years). Use in the elderly and in patients with mild to moderate organ impairment requires particular caution and must be carefully considered by a healthcare provider.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory information establishes the Diclomex (Diclofenac) interaction profile based on risks associated with co-administration and effects on systemic exposure. The use of Diclomex is formally avoided with other systemic NSAIDs, including cyclooxygenase-2 selective inhibitors, due to the potential for additive adverse effects. Co-administration is contraindicated in the setting of perioperative pain related to Coronary Artery Bypass Graft (CABG) surgery.

Documented Pharmacological Interactions

Interaction Type Interacting Medicines and Substances
Increased Bleeding Risk (PD) Anticoagulants, Antiplatelet agents, Systemic Corticosteroids, SSRIs
Increased Exposure (PK) Voriconazole (a strong CYP2C9 inhibitor)
Renal Function Risk (PD) ACE Inhibitors, ARBs, Diuretics
Substance Interaction Alcohol (increases risk of GI bleeding)

Co-administration with Voriconazole is documented to significantly increase Diclofenac's systemic exposure (Cmax and AUC). Furthermore, the regulatory profile highlights that the consequences of interactions resulting in gastrointestinal bleeding are generally more serious in the elderly. When combined with diuretics, ACE inhibitors, or ARBs, special renal function monitoring is specified for patients with impaired renal or cardiac function.

Mechanism of Action

How Diclomex Works

The mechanism of action for Diclomex (Diclofenac) is defined by its targeted influence on two key pharmacological domains: the inhibition of chemical mediators and the direct modulation of neural nociceptive signaling.


Inhibition of Prostanoid Synthesis

This primary mechanism involves the drug acting as a competitive inhibitor of the Cyclooxygenase (COX) enzymes (both COX-1 and COX-2). By restricting the function of these enzymes, Diclomex suppresses the Arachidonic Acid Cascade and decreases the systemic and local formation of prostaglandins . This modification of mediator synthesis leads directly to the modulation of inflammatory signaling and influences the central control of body temperature, contributing to thermoregulatory adjustment.


Modulation of Peripheral Nociceptive Signals

Beyond its enzyme-blocking action, the drug exerts multiple mechanistic influences on nociceptive signal transduction at the nerve level. This involves engaging mechanisms that affect peripheral Acid-Sensing Ion Channels (ASICs) and inhibiting the release of certain neuropeptides, such as Substance P, from nerve terminals. This modulation directly interferes with the signaling patterns of nociceptive neurons, leading to alterations in the excitability of peripheral nerve endings and modulation of nociceptive response.

Dosage and Administration Information

How to Use Diclomex: Official Administration Guidelines

The usage of Diclofenac (Diclomex) is determined by its specific formulation and established guidelines. The guiding principle for administration is to use the lowest effective dose for the shortest duration necessary, which is a standard practice for this medication class.

Administration Routes and Standard Dosing

Diclomex is available via several approved administration routes, including oral (tablets, capsules, powder), topical (gels, solutions), and parenteral (Intravenous or Intramuscular injection).

Route / Form Dosing Pattern (Examples) Administration Instruction
Oral (Delayed/Extended Release) Total daily doses commonly range from 100 mg to 150 mg, often given in divided doses or once daily. Must be swallowed whole; do not crush or chew these forms to preserve the controlled release.
Oral (Immediate Release Powder) Used for acute episodes; typically a single 50 mg dose. Must be mixed with water and taken on an empty stomach for optimal absorption.
Intravenous (IV) Restricted to short-term management (e.g., up to 2 days) in a supervised setting. Typical doses are 37.5 mg every 6 hours, not exceeding 150 mg daily. Must be diluted immediately before use and administered as an infusion; only specific regimens allow a short bolus injection.
Topical (Gel) Applied to the affected area (e.g., knee) often twice daily, according to the specified dispensing unit (e.g., 2g or 4g units). Apply only to intact skin and avoid contact with mucous membranes.

Use Patterns and Adjustments

For chronic conditions like arthritis, the drug may be used for long-term symptom management but requires adherence to the minimal effective dose. For specific populations, the lowest effective dose is routinely recommended for older adults due to general health considerations. Dosage adjustments for mild to moderate renal or hepatic impairment are typically not necessary, but monitoring is advised.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Mechanism of Action Studies

Preclinical research evaluated the drug's properties, finding that it acts as a selective inhibitor of the Janus kinase (JAK) family. Evidence from in-vitro and animal models supports this finding.

Studies investigated the relationship between this inhibition and the immune response. Research has explored whether the administration of the drug was associated with changes in the release of pro-inflammatory cytokines. Researchers continue to evaluate the implications of these findings.

Clinical Efficacy Trials

A number of randomized controlled trials (RCTs) and open-label extension studies were conducted to examine the medication in adults.

Pain and Symptom Management

One study evaluated the administration of the new medication in combination with standard analgesics and compared it to either treatment alone. Findings reported that participants receiving the combination had lower average pain scores over a 12-week period compared to the monotherapy groups.

Another Phase 3 RCT assessed the effect of the monotherapy drug on a composite symptom score (including fatigue, pain, and joint swelling) in a population with active disease. The study measured the proportion of participants receiving the drug who reached a specified level of symptom score change, reporting a difference compared to placebo at the 24-week endpoint.

Long-term Disease Activity

Studies have also examined the long-term profile of the medication. An observational study tracked participants for up to two years. Researchers evaluated whether participants who maintained treatment had changes in disease activity scores at 104 weeks compared to baseline. A meta-analysis summarized findings related to disease activity over 52 weeks. The data are being examined to understand whether they indicate long-term differences.

Safety and Tolerability

Dosing and Administration

Studies examining drug tolerance typically involved starting with a lower dose and gradually increasing it, with researchers monitoring for gastrointestinal side effects. The studies documented specific adverse events, which included mild headache and temporary nausea. Participants in the highest dose cohort reported the highest incidence of these events.

Specific Patient Populations

Studies evaluated the tablet formulation, including one that examined the safety profile in a small group of individuals with mild liver impairment. The treatment was not evaluated in individuals with X condition. Assessment of risks versus benefits is a determination made by a healthcare professional.

Key Studies & References

  1. Comparative efficacy and safety of JAK inhibitors as monotherapy and in combination with methotrexate in patients with active rheumatoid arthritis: A systematic review and meta-analysis
  2. Impact of Tofacitinib on the Individual Components of the ACR Composite Score in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of Phase 3 Trials

Frequently Asked Questions (FAQ)

Common questions about Diclomex (FAQ)


Q: How quickly does Diclomex start working after taking it?

Regulatory documents indicate that Diclomex's onset of action is often reported within 30 minutes for non-gel oral formulations. For topical gel forms, the expected onset of action may take longer, generally described as occurring within four hours of application to the skin.


Q: What is the expected duration of action for one dose of Diclomex?

The time it takes for the body to clear half of the active ingredient (the elimination half-life) is typically short, about 1.2 to 2 hours. However, the duration of pain relief after a single dose is commonly reported in studies to last for up to eight hours, depending on the specific formulation.


Q: Is Diclomex generally considered appropriate for use by the elderly?

Official documentation notes that the use of Diclomex in older adults is associated with a documented increased risk of serious adverse effects, including cardiovascular events and gastrointestinal bleeding. For this reason, official guidelines specify using the lowest effective dose for the shortest duration possible in this population.


Q: Are there any known interactions between Diclomex and alcohol?

Yes, official documents describe a pharmacological interaction where the use of alcohol along with Diclomex may increase the risk of gastrointestinal (GI) bleeding. This is noted as compounding the stomach-related risk already associated with this class of medicine.


Q: What happens if a user misses a dose (non-directive, informational)?

Patient information leaflets often describe a standard procedure where a missed dose should be taken as soon as it is remembered, unless it is nearly time for the next scheduled dose. If that is the case, the individual should revert to their regular schedule. The guidelines specify that taking a double dose to compensate for a missed dose is to be avoided.


Q: Is Diclomex a medicine that can be used for long-term conditions?

Diclomex is indicated in regulatory documents for the management of symptoms associated with chronic conditions like arthritis. When its use extends over long periods, official labeling mandates that patients should be periodically reviewed for treatment effectiveness and risk factors, emphasizing the use of the lowest effective dose.


Q: Why are people often told to take Diclomex with food?

The instruction to administer Diclomex with food, milk, or an antacid is often included in patient information materials as a strategy documented to manage the potential for gastrointestinal side effects. This method aims to protect against common issues like stomach irritation or indigestion.


Q: Can Diclomex be taken at the same time as other over-the-counter pain relievers?

Regulatory guidance advises against combining Diclomex with other pain relievers in the NSAID class (like ibuprofen or naproxen) due to the risk of increased side effects. However, combination with non-NSAID relievers like paracetamol (acetaminophen) is generally considered acceptable. Any combination of medications should be reviewed against the interaction profile by a healthcare professional.


Q: Does Diclomex interact with common supplements like magnesium or fish oil?

Official information notes that certain supplements may require caution. The use of supplements with antiplatelet effects, such as those containing omega-3 fatty acids (fish oil), is noted as requiring caution due to the potential for increased bleeding risk when combined with Diclomex.


Q: Is there any information available about Diclomex use while breastfeeding?

Yes, official regulatory documentation indicates that the active substance of Diclomex and its metabolites pass into breast milk in small amounts. The decision on whether to use the medicine during this period is described as needing to be based on a risk-benefit assessment by a healthcare professional.


Q: Does Diclomex interact with birth control pills?

Diclomex is documented to potentially interact with certain types of oral contraceptives, specifically those containing the ingredient drospirenone. This combination may lead to increased potassium levels in the blood, a condition that requires clinical monitoring.


Q: Are there any dietary restrictions mentioned in the official materials for Diclomex?

There are no broad dietary restrictions or specific foods listed as forbidden in official labeling beyond general guidance on taking the medicine with food. The most significant substance-related warning in the regulatory profile involves the consumption of alcohol.


Q: Is Diclomex available over-the-counter in any country?

The availability of Diclomex (Diclofenac) varies across global regions. While higher-strength systemic forms are often prescription-only ( Rx), certain lower-strength formulations or topical gels are available as over-the-counter (OTC) medicines in some countries, such as the US and the UK.


Q: Have there been recent updates to the official safety warnings for Diclomex?

Regulatory agencies routinely review and update safety information for Diclomex through ongoing pharmacovigilance programs. This includes assessments on serious risks, such as cardiovascular risk and the potential for gastrointestinal complications, resulting in periodic label changes and public safety warnings.


Q: What should a patient know about the potential for allergic reactions to Diclomex?

Official safety information documents specific signs of an allergic or hypersensitivity reaction, which can include severe symptoms. These may involve swelling of the face, lips, tongue, or throat, difficulty breathing or wheezing, and severe skin reactions such as widespread rash or hives. The development of any signs of an allergic reaction requires immediate medical attention.


Q: Is it normal to experience mild swelling of the hands or feet with Diclomex?

Official documentation for Diclomex lists fluid retention and edema (swelling) as reported adverse reactions associated with its use. This may affect the peripheral tissues, such as the hands and feet. The documentation of this reaction is important for the safety record.


Q: Does the time of day matter when taking Diclomex?

The official product information does not mandate a universal time of day for taking Diclomex, as timing often depends on the specific formulation and condition being treated. The most important factor is adhering to the prescribed frequency to maintain steady drug levels.


Q: What is the difference in purpose between the various strengths of Diclomex?

Official labeling specifies different dose strengths and patterns for different medical purposes. For example, lower dose regimens may be indicated for chronic conditions like mild arthritis, while higher doses may be documented for treating acute pain or severe inflammatory episodes.


Q: Do studies suggest Diclomex can be used for relief of menstrual pain?

Yes, in many regulatory jurisdictions, Diclomex is specifically approved and listed as a therapeutic indication for the relief of primary dysmenorrhea (menstrual pain). This is in addition to its general indications for other pain and inflammatory conditions.


Q: How is the safety of Diclomex continuously monitored by regulatory agencies?

Regulatory agencies continuously monitor the safety profile of Diclomex through pharmacovigilance programs. This involves the systematic collection, assessment, and review of reported adverse drug reactions from patients and healthcare professionals to ensure the official product information remains accurate.


Q: Is Diclomex associated with any risk of dependence or addiction?

Diclomex (Diclofenac) is typically not classified as a controlled substance by major regulatory bodies. Therefore, the medicine is not associated with a risk of dependence or addiction in official regulatory warnings.


Q: Can Diclomex affect the results of common laboratory tests?

Official labeling notes that Diclomex can affect the results of certain laboratory tests. For example, a transient increase in liver enzymes is listed as a common adverse reaction, and its use may impact results related to renal function or blood counts.


Q: What are the official guidelines regarding using Diclomex if you have asthma?

Diclomex is contraindicated in patients who have a history of allergic-type reactions (such as asthma or hives) after taking aspirin or other NSAIDs. For individuals with asthma that is not related to aspirin sensitivity, official guidance typically advises that Diclomex should be used with caution.


Q: Does Diclomex affect driving ability or operating machinery?

Official regulatory labeling includes a warning regarding the effect on ability to drive. The presence of side effects such as dizziness, vertigo, drowsiness, or visual disturbances while taking Diclomex is officially documented as affecting the ability to drive or operate potentially hazardous machinery.


Q: Is Diclomex considered a Schedule 4 medicine?

The regulatory scheduling of Diclomex depends on the specific country and formulation. While it is commonly classified as prescription-only ( Rx), certain topical or lower-concentration forms may be listed in less restrictive schedules, such as Schedule III or be Unscheduled, depending on national regulations.


Q: Have there been any major recalls or safety alerts for Diclomex in the past five years?

Regulatory agencies frequently issue safety alerts and, in specific cases, product recalls related to Diclomex. For instance, the FDA has issued alerts regarding the discovery of undeclared active ingredients, including Diclofenac, in certain dietary supplements, which led to the recall of those specific products.


Q: What is the expected timeline for reviewing Diclomex's official safety profile?

Regulatory bodies conduct detailed periodic safety updates and reviews of the drug’s profile, often following a recurring cycle (e.g., every one to five years). The timeline for a major, comprehensive review can span several months or years as committees analyze the incoming data.


Q: Is Diclomex licensed for use in children?

Official regulatory documents typically state that the safety and efficacy of Diclomex have not been established for the general pediatric population (e.g., under 12 or 16 years of age). Therefore, general use in this age group is not usually licensed or recommended.


Q: Does Diclomex have an effect on sleep quality?

The official listing of adverse reactions for Diclomex includes Central Nervous System (CNS) effects such as drowsiness and insomnia (difficulty sleeping). While not a universally experienced effect, these symptoms are documented and may impact sleep quality.


Q: Can Diclomex cause an increased sensitivity to sunlight?

Yes, official documentation, particularly for the topical formulations, includes warnings about the potential for Diclomex to cause an increased sensitivity to sunlight, a side effect known as photosensitivity. Patients may be advised to avoid direct or excessive sun exposure during treatment.


Q: What is the documented maximum duration of use described in official labeling?

For the relief of acute pain, regulatory labeling often specifies that Diclomex should be used for the shortest duration possible, commonly not exceeding 7 to 10 days. For chronic conditions, the duration may be longer but is always subject to periodic physician review to manage long-term risks.


Q: Does Diclomex interact with commonly prescribed medicines for depression or anxiety?

Diclomex is known to interact with certain classes of antidepressants, specifically Selective Serotonin Reuptake Inhibitors (SSRIs), which significantly increases the risk of gastrointestinal bleeding. Similar bleeding risks are also described for other antidepressant classes like Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs).


Q: Why is Diclomex sometimes linked to liver function concerns?

Official documentation links Diclomex to liver function concerns because it is known to cause transient increases in liver enzymes in some individuals. Additionally, rare but severe cases of drug-induced liver injury have been documented in post-marketing surveillance, a finding that warrants careful monitoring.

How should Diclomex be stored and disposed of?

Storage and Disposal of Diclomex (Diclofenac)

The storage and disposal of Diclomex must adhere strictly to official regulatory requirements to ensure product integrity and public safety.

Official Storage Conditions

Requirement Specification
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Handling Rule Do not freeze (mandatory for topical gel formulations).
Protection Keep out of the reach and sight of children.
Container Rule Keep the container tightly closed (especially for topical gels).

Disposal Instructions

Unused or expired Diclofenac should be discarded using the regulatory-preferred method, which is a drug take-back program or mail-back service. If take-back is unavailable, the product must be mixed with an unappealing substance, such as dirt or cat litter, sealed in a container, and placed in the household trash. All personal information must be removed from the packaging prior to disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Diclomex found in:

A-Z Index: